Investigational Distone Deacetylase Inhibitors (HDACi) in Myeloproliferative Neoplasms

Researchers from a recent study suggest that HDACi are clearly active in MPN and there is good preclinical rationale for this. Their combination with ruxolitinib in myelofibrosis is promising, but note that the long-term tolerability of these agents is an important concern.

 Expert Opin Investig Drugs

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.